Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05130437 · ClinicalTrials.gov registry record · Phase 1

A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study

A Phase 1 study of Propionic Acidemia, sponsored by ModernaTX.

Recruiting
Registry status
Phase 1
Development phase
50
Enrollment target
20
Study locations

NCT05130437 is a Phase 1 study of Propionic Acidemia that is actively recruiting participants, run by ModernaTX. The registered enrollment target is 50 participants, below the 217-participant average among 6 other Propionic Acidemia trials with a reported enrollment target (77% lower). The trial reports 20 study locations across 15 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05130437, a Phase 1 study of Propionic Acidemia, is actively recruiting participants, sponsored by ModernaTX.

RECRUITING
Registry status
Phase 1
Development phase
50 participants
Enrollment target
20
Study locations

Study Summary

The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).

Conditions Studied

Propionic Acidemia

Interventions

  • BIOLOGICAL mRNA-3927

Study Locations (20)

Other

  • AP-HM- Hôpital de La Timone - Marseille
  • Hôpital Necker - Enfants Malades - Paris
  • Universitair Medisch Centrum Utrecht - PPDS - Utrecht
  • Hospital Universitario 12 de Octubre - Madrid

California

  • Ronald Reagan UCLA Medical Center - Los Angeles
  • University of Stanford Medical Center - Palo Alto

Ar Riya

  • King Faisal Specialist Hospital & Research Centre - Riyadh
  • King Abdullah Children's Specialist Hospital - Riyadh

Michigan

  • University of Michigan Hospitals - Ann Arbor

New York

  • Icahn School of Medicine at Mount Sinai - New York

North Carolina

  • Duke University Medical System (Duke Health) - Durham

Pennsylvania

  • The Children's Hospital of Philadelphia (CHOP) - Philadelphia

Texas

  • Texas Children's Hospital - Houston

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2021-11-09
Est. Completion 2031-12-04
Phase Phase 1

Sponsor

ModernaTX

90 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05130437

The ClinicalTrials.gov registry entry for NCT05130437 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 217-participant average among 6 other Propionic Acidemia trials with a reported enrollment target (77% lower). The listed sponsor is ModernaTX, which has 90 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Propionic Acidemia appearing as the primary indexed condition, and to 1 intervention - of which mRNA-3927 is the first listed.

NCT05130437 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Other, California, Ar Riya.

Frequently Asked Questions

What is clinical trial NCT05130437 about?

NCT05130437 is a clinical study titled "A Study to Assess the Long-term Safety and Clinical Activity of mRNA-3927 in Participants Previously Enrolled in the mRNA-3927-P101 Study". The main purpose of this study is to evaluate the long-term safety of mRNA-3927 administered to participants with propionic acidemia (PA) who have previously participated in Study mRNA-3927-P101 (NCT04159103).

What is the current status of trial NCT05130437?

This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2021-11-09. Estimated completion is 2031-12-04.

What conditions does trial NCT05130437 study?

This clinical trial studies the following conditions: Propionic Acidemia.

What interventions are being tested in trial NCT05130437?

The interventions under investigation include: mRNA-3927 (BIOLOGICAL).

Who is sponsoring clinical trial NCT05130437?

This trial is sponsored by ModernaTX, which has 90 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05130437 being conducted?

This trial has 20 study locations across California, Michigan, New York, North Carolina, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Propionic Acidemia

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Propionic Acidemia

All registered trials for this condition

California

All trials with a study site in California

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.